Necchi, A., Jong, J. J. D., Cigliola, A., Proudfoot, J. A., Tateo, V., Piacentini, M., Latini, G., Pastorino, G. L., Crupi, E., Colecchia, M., Brembilla, G., Moschini, M., Davicioni, E., Briganti, A., Montorsi, F., Maiorano, B. A., Mercinelli, C. (2026). Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4617